Olaparib is Used for treating various types of cancers, including breast, ovarian, pancreatic, and metastatic prostate cancer, in patients with specific gene mutations undergoing specific chemotherapy regimens. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Lynparza on Dec 19, 2014.

Olaparib Patents

Given below is the list of patents protecting Olaparib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Lynparza	US11970530	Methods of treating homologous recombination deficient cancer	Oct 25, 2041	Astrazeneca
Lynparza	US8859562	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug 04, 2031	Astrazeneca
Lynparza	US8475842	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Dec 31, 2029	Astrazeneca
Lynparza	US11633396	Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one	Oct 07, 2029	Astrazeneca
Lynparza	US11975001	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Oct 07, 2029	Astrazeneca
Lynparza	US12048695	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Oct 07, 2029	Astrazeneca
Lynparza	US12144810	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Oct 07, 2029	Astrazeneca
Lynparza	US12178816	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Oct 07, 2029	Astrazeneca
Lynparza	US8247416	Phthalazinone derivative	Sep 24, 2028	Astrazeneca
Lynparza	US7449464	Phthalazinone derivatives	Sep 08, 2027	Astrazeneca
Lynparza	US8071579	DNA damage repair inhibitors for the treatment of cancer	Aug 12, 2027	Astrazeneca
Lynparza	US8143241	DNA damage repair inhibitors for treatment of cancer	Aug 12, 2027	Astrazeneca
Lynparza	US7449464	Phthalazinone derivatives	Oct 11, 2024 (Expired)	Astrazeneca
Lynparza	US7981889	Phthalazinone derivatives	Oct 11, 2024 (Expired)	Astrazeneca
Lynparza	US8912187	Phthalazinone derivatives	Mar 12, 2024 (Expired)	Astrazeneca
Lynparza	US9169235	Phthalazinone derivatives	Mar 12, 2024 (Expired)	Astrazeneca
Lynparza	US9566276	Phthalazinone derivatives	Mar 12, 2024 (Expired)	Astrazeneca
Lynparza	US7151102	Phthalazinone derivatives	Apr 29, 2022 (Expired)	Astrazeneca

Add above patents to watchlist

Olaparib's Family Patents

Full family tree